NurExone Biologic Inc. (TSX.V: NRX) (OTCQB: NRXBF) (FSE: J90) has been awarded first place in the Healthcare category at the BOLD Awards VII Gala, held March 27, 2026, in Barcelona. The award recognizes the company's leadership in developing exosome-based therapies for central nervous system (CNS) injuries, as selected by a panel of global industry leaders. This honor underscores NurExone's potential to address significant unmet medical needs in conditions such as acute spinal cord and optic nerve injuries.
In conjunction with the award, NurExone announced plans to engage Investor Brand Network (IBN), subject to approval from the TSX Venture Exchange, to support its investor awareness efforts. The engagement, set to begin April 1, 2026, involves a one-year agreement with a monthly fee of $6,500. IBN will distribute news and updates across more than 5,000 outlets, aiming to strengthen market visibility and long-term shareholder value.
NurExone is focused on regenerative exosome-based therapies for CNS injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data, supporting its clinical potential. The company has achieved regulatory milestones, including Orphan Drug Designation, which facilitates the roadmap toward clinical trials in the United States and Europe. Commercially, NurExone expects to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. The company has established Exo-Top, a U.S. subsidiary, to anchor its North American activity and growth strategy.
The award and investor outreach initiatives signal NurExone's commitment to advancing its pipeline and enhancing shareholder communication. For more information, visit the full press release at https://ibn.fm/cWtqT.
